161 related articles for article (PubMed ID: 3132636)
1. Oxalate metabolism in end-stage renal disease: the effect of ascorbic acid and pyridoxine.
Morgan SH; Maher ER; Purkiss P; Watts RW; Curtis JR
Nephrol Dial Transplant; 1988; 3(1):28-32. PubMed ID: 3132636
[TBL] [Abstract][Full Text] [Related]
2. Plasma concentration and peritoneal clearance of oxalate in patients on continuous ambulatory peritoneal dialysis (CAPD).
Yamauchi A; Fujii M; Shirai D; Mikami H; Okada A; Imai E; Ando A; Orita Y; Kamada T
Clin Nephrol; 1986 Apr; 25(4):181-5. PubMed ID: 3698351
[TBL] [Abstract][Full Text] [Related]
3. Plasma oxalate concentration, oxalate clearance and cardiac function in patients receiving haemodialysis.
Tomson CR; Channon SM; Ward MK; Laker MF
Nephrol Dial Transplant; 1989; 4(9):792-9. PubMed ID: 2516611
[TBL] [Abstract][Full Text] [Related]
4. Effects of ascorbic acid and pyridoxine supplementation on oxalate metabolism in peritoneal dialysis patients.
Shah GM; Ross EA; Sabo A; Pichon M; Reynolds RD; Bhagavan H
Am J Kidney Dis; 1992 Jul; 20(1):42-9. PubMed ID: 1621677
[TBL] [Abstract][Full Text] [Related]
5. [The effect of hemodialysis and continuous ambulatory peritoneal dialysis on renal anemia].
Stojimirović B; Grujić-Adanja G
Srp Arh Celok Lek; 1997; 125(5-6):163-7. PubMed ID: 9265238
[TBL] [Abstract][Full Text] [Related]
6. Oxalate dynamics and removal rates during haemodialysis and peritoneal dialysis in patients with primary hyperoxaluria and severe renal failure.
Watts RW; Veall N; Purkiss P
Clin Sci (Lond); 1984 May; 66(5):591-7. PubMed ID: 6368103
[TBL] [Abstract][Full Text] [Related]
7. Reduction of elevated plasma oxalic acid by pyridoxine therapy in patients on RDT.
Balcke P; Schmidt P; Zazgornik J; Kopsa H
Proc Eur Dial Transplant Assoc; 1983; 19():308-12. PubMed ID: 6878246
[TBL] [Abstract][Full Text] [Related]
8. Secondary hyperoxalemia caused by vitamin C supplementation in regular hemodialysis patients.
Ono K
Clin Nephrol; 1986 Nov; 26(5):239-43. PubMed ID: 3802587
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of vitamin B6 and its requirement in chronic renal failure.
Mydlík M; Derzsiová K; Zemberová E
Kidney Int Suppl; 1997 Nov; 62():S56-9. PubMed ID: 9350682
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of serum sialic acid concentration in chronic renal failure children on continuous ambulatory peritoneal dialysis and hemodialysis].
Szprynger K; Szczepańska M; Mazur B; Dyduch A; Zwolińska D; Morawiec-Knysak A; Makulska I
Pol Merkur Lekarski; 2000 Jul; 8(49):459-61. PubMed ID: 11070713
[TBL] [Abstract][Full Text] [Related]
11. Long-term, low-dose, intravenous vitamin C leads to plasma calcium oxalate supersaturation in hemodialysis patients.
Canavese C; Petrarulo M; Massarenti P; Berutti S; Fenoglio R; Pauletto D; Lanfranco G; Bergamo D; Sandri L; Marangella M
Am J Kidney Dis; 2005 Mar; 45(3):540-9. PubMed ID: 15754276
[TBL] [Abstract][Full Text] [Related]
12. Continuous ambulatory peritoneal dialysis: three years' experience.
Ramos JM; Gokal R; Siamopolous K; Ward MK; Wilkinson R; Kerr DN
Q J Med; 1983; 52(206):165-86. PubMed ID: 6611839
[TBL] [Abstract][Full Text] [Related]
13. Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria.
Milliner DS; Eickholt JT; Bergstralh EJ; Wilson DM; Smith LH
N Engl J Med; 1994 Dec; 331(23):1553-8. PubMed ID: 7969325
[TBL] [Abstract][Full Text] [Related]
14. The effect of pyridoxine on oxalate dynamics in three cases of primary hyperoxaluria (with glycollic aciduria).
Watts RW; Veall N; Purkiss P; Mansell MA; Haywood EF
Clin Sci (Lond); 1985 Jul; 69(1):87-90. PubMed ID: 4064559
[TBL] [Abstract][Full Text] [Related]
15. [Clinical aspects of oxalate metabolism].
Balcke P
Infusionsther Klin Ernahr; 1983 Dec; 10(6):318-21. PubMed ID: 6662594
[TBL] [Abstract][Full Text] [Related]
16. Increased excretion of nitric oxide in exhaled air of patients with chronic renal failure.
Matsumoto A; Hirata Y; Kakoki M; Nagata D; Momomura Si; Sugimoto T; Tagawa H; Omata M
Clin Sci (Lond); 1999 Jan; 96(1):67-74. PubMed ID: 9857108
[TBL] [Abstract][Full Text] [Related]
17. Evolution of residual renal function in patients undergoing maintenance haemodialysis or continuous ambulatory peritoneal dialysis.
Rottembourg J; Issad B; Gallego JL; Degoulet P; Aime F; Gueffaf B; Legrain M
Proc Eur Dial Transplant Assoc; 1983; 19():397-403. PubMed ID: 6878254
[TBL] [Abstract][Full Text] [Related]
18. Continuous ambulatory peritoneal dialysis vs haemodialysis: a lesser risk of amyloidosis?
Tielemans C; Dratwa M; Bergmann P; Goldman M; Flamion B; Collart F; Wens R
Nephrol Dial Transplant; 1988; 3(3):291-4. PubMed ID: 3140103
[TBL] [Abstract][Full Text] [Related]
19. Oxalate clearance by haemodialysis--a comparison of seven dialysers.
Franssen CF
Nephrol Dial Transplant; 2005 Sep; 20(9):1916-21. PubMed ID: 15998647
[TBL] [Abstract][Full Text] [Related]
20. Recurrence of oxalate deposition in a renal transplant during ciclosporin A therapy.
Drachman R; Dollberg L; Drukker A
Child Nephrol Urol; 1988-1989; 9(1-2):90-2. PubMed ID: 3075154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
